Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...

A recent report reveals an increase in cancer cases among children treated with Bluebird Bio's Skysona gene therapy, raising ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Stellantis (STLA) confirmed that its CEO Carlos Tavares will retire in early 2026 at the end of his contract. Read more ...

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood ...

Seven out of 67 children who were given bluebird's (BLUE) gene therapy Skysona during clinical trials ended up developing ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...

Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.

The recent publication in the New England Journal of Medicine highlighting an increased incidence of hematologic cancers in patients treated with Bluebird Bio’s Skysona product has raised concerns.

Seven children treated with bluebird bio ’s gene therapy Skysona for cerebral adrenoleukodystrophy, a rare and progressive neurodegenerative disease, developed blood cancers, according to a study ...

While the use of elivaldogene autotemcel (eli-cel; Skysona) gene therapy has demonstrated long-term efficacy in patients with ...